Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation

References

• Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, . Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51:443–7.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. Adv Immunol. 1987;40:379–438.
   PubMed Web of Science ®Google Scholar
• Ikehara S. A new concept of stem cell disorders and their new therapy. J Hematother Stem Cell Res. 2003;12:643–53.
   PubMedGoogle Scholar
• Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007; 150:197–214.
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, . Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–8.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, . Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–14.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol. 2004;83: 551–65.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.
   PubMed Web of Science ®Google Scholar
• Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.
   PubMed Web of Science ®Google Scholar
• Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426–34.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, . Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98.
   PubMed Web of Science ®Google Scholar
• Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5:485–9.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, . Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389–98.
   PubMed Web of Science ®Google Scholar
• Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:637–45.
   PubMed Web of Science ®Google Scholar
• Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, . Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant. 2007;7: 336–46.
   Google Scholar
• Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, . Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–7.
   PubMed Web of Science ®Google Scholar
• Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992–9.
   PubMed Web of Science ®Google Scholar
• Gao L, Chen X, Zhang X, Liu Y, Kong P, Peng X, . Human umbilical cord blood-derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34+ cells in vitro. Blood Cells Mol Dis. 2006;36:322–8.
   PubMed Web of Science ®Google Scholar
• Hao L, Zhang C, Chen XH, Zou ZM, Zhang X, Kong PY, . Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro. Croat Med J. 2009;50:351–60.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, . An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230–9.
   PubMed Web of Science ®Google Scholar
• Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol. 1986; 86:371–5.
   PubMed Web of Science ®Google Scholar
• Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, . Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93: 3140–7.
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–13.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ, . Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009;206:387–98.
   PubMedGoogle Scholar
• Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005; 105:4120–6.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080–7.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ge W, Li C, You S, Liao L, Han Q, . Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263–71.
   PubMed Web of Science ®Google Scholar
• Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, . Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317–26.
   PubMed Web of Science ®Google Scholar
• Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25− subpopulations. J Immunol. 2000;165:3105–10.
   PubMedGoogle Scholar
• Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001; 31:1247–54.
   PubMed Web of Science ®Google Scholar
• Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001;182:58–67.
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188: 287–96.
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells. J Immunol. 2001;167:1137–40.
   PubMed Web of Science ®Google Scholar
• Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, Cumano A, Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J Immunol. 2000;164:3573–80.
   Google Scholar
• Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol. 1994;153:400–11.
   PubMedGoogle Scholar
• Taylor PA, Noelle RJ, Blazar BR. CD4(+) CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001; 193:1311–8.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–99.
   PubMed Web of Science ®Google Scholar
• Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002; 99:3493–9.
   PubMed Web of Science ®Google Scholar
• Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, . Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516–25.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815–22.
   PubMed Web of Science ®Google Scholar
• Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest. 2008;37:29–42.
   PubMedGoogle Scholar
• von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338–44.
   PubMed Web of Science ®Google Scholar
• Picca CC, Caton AJ. The role of self-peptides in the development of CD4+ CD25+ regulatory T cells. Curr Opin Immunol. 2005;17:131–6.
   Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M, Streeter PR, Mauch KA, Frey MR, Raber A, van't Hof W, . Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 2009;255:55–60.
   PubMedGoogle Scholar
• Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55.
   PubMed Web of Science ®Google Scholar